




(A) MRI EOAD *APOE-ε4*- vs. *APOE-ε4*+




(B) Amyloid PET EOAD *APOE-ε4*- vs. *APOE-ε4*+




(C) MRI EOnonAD *APOE-ε4*- vs. *APOE-ε4*+




(D) Amyloid PET EOnonAD *APOE-ε4*- vs. *APOE-ε4*+



(E) MRI CN *APOE-ε4*- vs. *APOE-ε4*+



(F) Amyloid PET CN *APOE-ε4*- vs. *APOE-ε4*+



Supplementary Figure 2. Sex stratified by *APOE-ε4* carrier status. Imaging biomarker measures comparing *APOE-ε4* male carriers (+) vs. male non-carriers (-) and *APOE-ε4* female carriers (+) vs. female non-carriers (-): (A) EOAD hippocampal volume (B) EOAD global amyloid uptake (C) EOnonAD hippocampal volume (D) EOnonAD global amyloid uptake (E) CN hippocampal volume (F) CN global amyloid uptake.